Development of a novel plasma protein biomarker panel for a radiation/nuclear triage biodosimetry device (rapid RAD DX)
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93024C00006
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,148,018
Award facts
- Opportunity
-
- Development of Radiation/Nuclear Medical Countermeasures (MCMs) or Biodosimetry Devices Pre-Solicitation · BAA75N93022R00021 · Posted Nov 10, 2022
- Contract value 45% obligated
-
- $2,148,018.01 Current, with exercised options
- $4,756,378.01 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$1,851,542 | |
| Terminate for Convenience | $0 | |
| Exercise an Option | $1,999,778 | |
| Original award | $1,999,782 |
About this award
This is a $4,756,378.01 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to SRI International, a non-profit research and development institute. The contract is for the development of a novel plasma protein biomarker panel for a radiation/nuclear triage biodosimetry device, known as the "RAPID RAD DX" project. This effort supports NIAID's mission to develop products for the assessment, diagnosis, mitigation, and/or treatment of radiation injuries resulting from a radiological or nuclear incident. The contract does not have a small business set-aside designation. SRI International has a robust history of providing advanced scientific and technical services to the U.S. federal government across various domains, including through other indefinite delivery vehicle (IDV) contracts.
Quick answers
Who was awarded contract 75N93024C00006?
75N93024C00006 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 1, 2024.
How much is contract 75N93024C00006 worth?
The government has obligated $2,148,018 on 75N93024C00006. Its potential value, with all options, is $4,756,378.
Was contract 75N93024C00006 competed?
The extent of competition for 75N93024C00006 was full and open competition. The government received 9 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award